Chronic rhinosinusitis with nasal polyps - Pipeline Insight, 2025
Description
DelveInsight’s, “Chronic rhinosinusitis with nasal polyps - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Chronic rhinosinusitis with nasal polyps pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chronic rhinosinusitis with nasal polyps: Overview
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition affecting the nasal passages and sinuses, characterized by the growth of benign polyps. These polyps, which are soft, painless, and non-cancerous, arise from the mucous membranes and can obstruct the nasal airways, leading to significant breathing difficulties. Patients often experience symptoms such as nasal congestion, a reduced sense of smell, facial pain or pressure, and nasal discharge. The condition is distinct from other forms of chronic rhinosinusitis due to the presence of these polyps, which play a critical role in the chronic nature and severity of the disease.
The etiology of CRSwNP is multifactorial, involving a combination of genetic predisposition, environmental factors, and immune system dysfunction. Chronic inflammation is a hallmark of the disease, often driven by a skewed immune response favoring Type 2 inflammation, which involves cytokines such as IL-4, IL-5, and IL-13. This inflammatory pathway leads to tissue remodeling and polyp formation. Additionally, CRSwNP is commonly associated with other conditions like asthma, aspirin-exacerbated respiratory disease (AERD), and allergic rhinitis, indicating a broader systemic involvement. This association often complicates the management of the disease, as patients may present with a spectrum of symptoms and comorbidities requiring comprehensive treatment strategies.
Treatment for CRSwNP typically involves a combination of medical and surgical approaches aimed at reducing inflammation, shrinking polyps, and improving sinus drainage. First-line treatments often include intranasal corticosteroids to reduce local inflammation and polyp size. In more severe cases, systemic corticosteroids or biologic therapies targeting specific inflammatory pathways may be employed. Surgical intervention, such as functional endoscopic sinus surgery (FESS), is considered when medical management fails to provide relief. This procedure involves removing polyps and improving sinus drainage pathways, which can significantly enhance the quality of life for affected individuals. Ongoing research into the underlying mechanisms of CRSwNP continues to drive the development of more targeted and effective therapies.
""Chronic rhinosinusitis with nasal polyps- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic rhinosinusitis with nasal polyps pipeline landscape is provided which includes the disease overview and Chronic rhinosinusitis with nasal polyps treatment guidelines. The assessment part of the report embraces, in depth Chronic rhinosinusitis with nasal polyps commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic rhinosinusitis with nasal polyps collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Chronic rhinosinusitis with nasal polyps report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic rhinosinusitis with nasal polyps Emerging Drugs
Further product details are provided in the report……..
Chronic rhinosinusitis with nasal polyps: Therapeutic Assessment
This segment of the report provides insights about the different Chronic rhinosinusitis with nasal polyps drugs segregated based on following parameters that define the scope of the report, such as:
Chronic rhinosinusitis with nasal polyps: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic rhinosinusitis with nasal polyps therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic rhinosinusitis with nasal polyps drugs.
Chronic rhinosinusitis with nasal polyps Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Chronic rhinosinusitis with nasal polyps: Overview
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition affecting the nasal passages and sinuses, characterized by the growth of benign polyps. These polyps, which are soft, painless, and non-cancerous, arise from the mucous membranes and can obstruct the nasal airways, leading to significant breathing difficulties. Patients often experience symptoms such as nasal congestion, a reduced sense of smell, facial pain or pressure, and nasal discharge. The condition is distinct from other forms of chronic rhinosinusitis due to the presence of these polyps, which play a critical role in the chronic nature and severity of the disease.
The etiology of CRSwNP is multifactorial, involving a combination of genetic predisposition, environmental factors, and immune system dysfunction. Chronic inflammation is a hallmark of the disease, often driven by a skewed immune response favoring Type 2 inflammation, which involves cytokines such as IL-4, IL-5, and IL-13. This inflammatory pathway leads to tissue remodeling and polyp formation. Additionally, CRSwNP is commonly associated with other conditions like asthma, aspirin-exacerbated respiratory disease (AERD), and allergic rhinitis, indicating a broader systemic involvement. This association often complicates the management of the disease, as patients may present with a spectrum of symptoms and comorbidities requiring comprehensive treatment strategies.
Treatment for CRSwNP typically involves a combination of medical and surgical approaches aimed at reducing inflammation, shrinking polyps, and improving sinus drainage. First-line treatments often include intranasal corticosteroids to reduce local inflammation and polyp size. In more severe cases, systemic corticosteroids or biologic therapies targeting specific inflammatory pathways may be employed. Surgical intervention, such as functional endoscopic sinus surgery (FESS), is considered when medical management fails to provide relief. This procedure involves removing polyps and improving sinus drainage pathways, which can significantly enhance the quality of life for affected individuals. Ongoing research into the underlying mechanisms of CRSwNP continues to drive the development of more targeted and effective therapies.
""Chronic rhinosinusitis with nasal polyps- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic rhinosinusitis with nasal polyps pipeline landscape is provided which includes the disease overview and Chronic rhinosinusitis with nasal polyps treatment guidelines. The assessment part of the report embraces, in depth Chronic rhinosinusitis with nasal polyps commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic rhinosinusitis with nasal polyps collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic rhinosinusitis with nasal polyps R&D. The therapies under development are focused on novel approaches to treat/improve Chronic rhinosinusitis with nasal polyps.
This segment of the Chronic rhinosinusitis with nasal polyps report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic rhinosinusitis with nasal polyps Emerging Drugs
- GSK3511294: GlaxoSmithKline
- CM326: Keymed Biosciences Co.Ltd
Further product details are provided in the report……..
Chronic rhinosinusitis with nasal polyps: Therapeutic Assessment
This segment of the report provides insights about the different Chronic rhinosinusitis with nasal polyps drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chronic rhinosinusitis with nasal polyps
- There are approx. 8+ key companies which are developing the therapies for Chronic rhinosinusitis with nasal polyps. The companies which have their Chronic rhinosinusitis with nasal polyps drug candidates in the most advanced stage, i.e. Phase III include, GlaxoSmithKline.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Chronic rhinosinusitis with nasal polyps: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic rhinosinusitis with nasal polyps therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic rhinosinusitis with nasal polyps drugs.
Chronic rhinosinusitis with nasal polyps Report Insights
- Chronic rhinosinusitis with nasal polyps Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic rhinosinusitis with nasal polyps drugs?
- How many Chronic rhinosinusitis with nasal polyps drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic rhinosinusitis with nasal polyps?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic rhinosinusitis with nasal polyps therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic rhinosinusitis with nasal polyps and their status?
- What are the key designations that have been granted to the emerging drugs?
- Keymed Biosciences Co.Ltd
- GlaxoSmithKline
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Guangdong Hengrui Pharmaceutical Co., Ltd
- CM326
- GSK3511294
- GR1802
- SHR-1905
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Chronic rhinosinusitis with nasal polyps: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Chronic rhinosinusitis with nasal polyps– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- GSK3511294: GlaxoSmithKline
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- CM326: Keymed Biosciences Co.Ltd
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Chronic rhinosinusitis with nasal polyps Key Companies
- Chronic rhinosinusitis with nasal polyps Key Products
- Chronic rhinosinusitis with nasal polyps- Unmet Needs
- Chronic rhinosinusitis with nasal polyps- Market Drivers and Barriers
- Chronic rhinosinusitis with nasal polyps- Future Perspectives and Conclusion
- Chronic rhinosinusitis with nasal polyps Analyst Views
- Chronic rhinosinusitis with nasal polyps Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
